What GIP Is
GIP stands for Glucose-dependent Insulinotropic Polypeptide, also historically known as Gastric Inhibitory Polypeptide. It is a 42-amino-acid incretin hormone secreted by enteroendocrine K-cells in the proximal small intestine (duodenum and jejunum) in response to nutrient intake — particularly fat and carbohydrate.
GIP is one of the two primary incretin hormones in human physiology. The other is GLP-1. Together they account for the majority of the "incretin effect" — the observation that an oral glucose load produces a substantially larger insulin response than the equivalent intravenous glucose load. The difference is the K-cell and L-cell hormonal signal triggered by nutrient passage through the gut.
The naming history GIP was originally named for its inhibitory effect on gastric acid secretion. The "insulinotropic" effect was characterised later, after which the abbreviation was retained but the expansion shifted from "Gastric Inhibitory" to "Glucose-dependent Insulinotropic". Modern literature uses both expansions interchangeably.
The GIP Receptor (GIPR) and Its Tissue Distribution
GIPR is a Class B G-protein-coupled receptor, structurally related to GLP-1R but with distinct ligand specificity. Tissue distribution differs from GLP-1R in important ways:
| Tissue | GIPR role | Mechanistic effect |
|---|---|---|
| Pancreatic beta cells | Glucose-dependent insulin secretion (parallel to GLP-1R) | Additive insulin response when both receptors co-engaged |
| Adipose tissue (white) | Lipogenesis, fat storage | Historically considered a barrier to weight loss via GIPR agonism |
| Adipose tissue (brown/beige) | Thermogenic gene expression | Newer research suggests pro-thermogenic role in some contexts |
| Hypothalamic centres | Appetite modulation | Complementary to GLP-1R signalling on satiety |
| Bone (osteoblasts, osteoclasts) | Bone remodelling regulation | Research interest in skeletal effects of GIPR agonism |
| CNS (hindbrain) | Reduced nausea/aversion signalling | Proposed mechanism for lower GI adverse-event burden vs GLP-1-only agonism |
The adipose tissue role of GIPR was historically considered a complication for weight-loss research — classical pharmacology suggested GIPR agonism should promote fat storage. Tirzepatide's clinical outcomes overturned that assumption: dual GLP-1R + GIPR agonism produces greater weight reduction than GLP-1R alone, not less. The current research interpretation is that chronic GIPR agonism produces receptor adaptation and net metabolic effects different from acute physiological GIP signalling.
Why Dual GLP-1/GIP Agonism (the "Twincretin" Class)
The therapeutic rationale for dual GLP-1R + GIPR agonism — the "twincretin" concept that produced Tirzepatide (LY3298176) — rests on three observations:
- Additive insulin secretion. GIPR and GLP-1R engage different intracellular pathways in beta cells. Co-agonism produces a larger insulin response than either alone, supporting tighter glucose control.
- Complementary appetite signalling. GIPR engagement appears to modulate hypothalamic appetite centres through pathways distinct from GLP-1R, adding to satiety without simply duplicating the same signal.
- Reduced GI adverse event burden. Hindbrain GIPR signalling appears to dampen the nausea/aversion response that GLP-1R engagement generates. SURMOUNT trial data shows lower nausea and discontinuation rates for Tirzepatide than would be predicted from a pure GLP-1R agonist at equivalent efficacy.
The result in clinical research: Tirzepatide's SURMOUNT-1 trial reported 20.9% mean weight reduction at 72 weeks at the 15mg dose, exceeding the 14.9% reported in Semaglutide's STEP 1 trial. For the full SURMOUNT analysis, see Tirzepatide SURMOUNT Trial Deep Dive.
Where GIPR Fits in the Multi-Receptor Research-Peptide Landscape
GIPR is now engaged by two of the three primary research-grade GLP-1 class peptides:
| Compound | GLP-1R | GIPR | Glucagon R | Class |
|---|---|---|---|---|
| Semaglutide | ✓ | — | — | Single (GLP-1R) |
| Tirzepatide | ✓ | ✓ | — | Dual (twincretin) |
| Retatrutide | ✓ | ✓ | ✓ | Triple agonist |
For researchers, the GIPR axis is a key variable distinguishing Semaglutide from the more recent compound generations. Research questions involving incretin synergy, beta-cell secretory dynamics, GI adverse-event mitigation, or the GIP-specific contributions to adipose biology are best addressed using dual or triple agonists rather than GLP-1-only compounds.
See GLP-1 Explained for the parent receptor context and Glucagon Receptor Explained for the third receptor that Retatrutide adds beyond the twincretin design.
Research Compounds Engaging GIPR
RetaLABS supplies research-grade Tirzepatide (dual GLP-1R + GIPR agonist) and Retatrutide (triple GLP-1R + GIPR + GcgR agonist) for Australian laboratory research. Both compounds bind GIPR as a primary mechanism alongside GLP-1R; Retatrutide adds the third receptor target. For the cross-compound comparison, see the GLP-1 Peptides Comparison Guide and the Retatrutide vs Tirzepatide guide.
Neither compound is approved as a therapeutic in Australia. Both are supplied strictly for laboratory research use.